Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis.
about
Biomarkers of therapeutic response in multiple sclerosis: current statusTherapeutic strategies for relapsing-remitting multiple sclerosis: a special focus on reduction of grey matter damage as measured by brain atrophy.Axonal degeneration in multiple sclerosis: can we predict and prevent permanent disability?Complement component C3 and butyrylcholinesterase activity are associated with neurodegeneration and clinical disability in multiple sclerosis.Tau or neurofilament light-Which is the more suitable biomarker for Huntington's disease?Lipocalin-2 is increased in progressive multiple sclerosis and inhibits remyelinationA changing treatment landscape for multiple sclerosis: challenges and opportunities.The current role of mitoxantrone in the treatment of multiple sclerosis.Dimethyl fumarate for treating relapsing multiple sclerosis.Neuroproteomics and microRNAs studies in multiple sclerosis: transforming research and clinical knowledge in biomarker research.The cerebrospinal fluid in multiple sclerosis: far beyond the bands.The clinical perspective: How to personalise treatment in MS and how may biomarkers including imaging contribute to this?Cerebrospinal fluid markers of neuronal and glial cell damage to monitor disease activity and predict long-term outcome in patients with autoimmune encephalitis.Neurofilament light chain predicts disease activity in relapsing-remitting MS.Monitoring disease activity in multiple sclerosis using serum neurofilament light protein.The role of blood and CSF biomarkers in the evaluation of new treatments against multiple sclerosis.Fluid biomarker and electrophysiological outcome measures for progressive MS trials.Defining active progressive multiple sclerosis.Vitamin D and axonal injury in multiple sclerosis.Any evident MRI T2 lesion activity should guide change of therapy in multiple sclerosis--commentary.Fluid biomarkers for disease activity in multiple sclerosis.Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple sclerosis.Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod.White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation.Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis.Neurofilament light chain as a biological marker for multiple sclerosis: a meta-analysis studyThe only certain measure of the effectiveness of multiple sclerosis therapy is cerebrospinal neurofilament level—NO
P2860
Q27012726-F3B30CBE-9359-4F09-B447-BA501DFB4374Q30869048-D9DD291A-3F38-4F34-9DD7-040FCBE6101FQ34570124-C9233DCC-7A20-4BC5-8F2F-B9BD4A1771B0Q35250966-DBECF24E-C241-454A-973E-4C6695B87CAFQ36291565-5D9F16BD-3568-4DCE-86F3-E454559B2025Q36451661-5613E560-53E8-42B0-8976-C358808172FEQ38180166-718192E1-6209-468E-A6C0-6007C9A7E9C9Q38212259-2487975F-3EAD-4869-B9A3-090510A03E06Q38266397-0DE96913-5B13-42B8-B48A-46A4C5EE7E4FQ38610689-D4EDB5C4-AB1C-4D62-8345-89B4FAD2F025Q38819421-A77F006E-BD2D-4CF8-ACC8-7CBDED20E947Q38910574-AB8BCB76-B660-497B-95A2-82EAF5A5276DQ40047133-F1008748-A344-491E-B7F1-290D016C8FE4Q47138197-C8E9224B-86CF-42F3-B647-68BA2E058034Q47144073-44F5031D-CAE6-40CC-A6EB-0C3946E3E6CCQ47579410-86D51BDE-404E-4330-B556-67F1A39CFA2CQ47638443-3D9C52FD-2DFC-487C-B8C2-41907A661F9EQ47918387-019D53C2-1590-4B56-9896-830D8D560049Q47987955-5DCD99A4-3534-4E45-BCA0-1DE3E068BF6BQ48359316-F8A8B78D-FF3A-4B9A-B4CB-FC42BA1C709AQ49562907-06A69919-ECD1-4FBE-958C-CAB70FB7B70BQ51359685-26596088-26DF-4AF1-9D22-46932954543FQ53212006-118E2223-85DB-4B39-B05B-B60CE5F7C5D9Q53396427-8C8E962A-B774-417D-AE4E-560956D3784EQ53624114-5495209B-4562-4F83-A253-B9C38D89AD34Q57161829-B5CAE273-68B3-4C6B-B124-5B5F719E5BFFQ57601807-5F8981AE-CC13-4EBA-BA9D-A265FADFDD84
P2860
Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis.
@en
Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis.
@nl
type
label
Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis.
@en
Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis.
@nl
prefLabel
Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis.
@en
Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis.
@nl
P2093
P2860
P50
P356
P1476
Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis.
@en
P2093
Markus Axelsson
Martin Gunnarsson
Peter Sundström
P2860
P356
10.1177/1352458513490544
P577
2013-05-23T00:00:00Z